Group One Trading, L.P. Bio Line Rx Ltd. Transaction History

Group One Trading, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.03 - $1.56 $3,283 - $4,973	3,188 New	3,188 $3,000
Q4 2022 Feb 09, 2023	SELL	$0.57 - $0.95 $3,724 - $6,208	-6,535 Reduced 67.91%	3,088 $1,000
Q2 2022 Aug 11, 2022	SELL	$1.06 - $1.82 $318 - $546	-300 Reduced 3.02%	9,623 $12,000
Q1 2022 May 12, 2022	SELL	$1.46 - $2.18 $1,314 - $1,962	-900 Reduced 8.32%	9,923 $17,000
Q4 2021 Feb 11, 2022	BUY	$1.98 - $3.06 $12,745 - $19,697	6,437 Added 146.76%	10,823 $22,000
Q3 2021 Nov 12, 2021	BUY	$2.65 - $3.35 $11,622 - $14,693	4,386 New	4,386 $12,000

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.